Agennix AG Announces Talactoferrin Data to be Presented at ASCO 2011 Annual Meeting

Planegg/Munich (Germany), Princeton, NJ and Houston, TX, June 1, 2011 – Agennix AG (Frankfurt Stock Exchange: AGX) today announced that new data from Phase II trials in non-small cell lung cancer and in severe sepsis with talactoferrin, an oral biologic therapy with immunomodulatory and antibacterial properties, will be presented at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 3-7, 2011 in Chicago, Illinois. Talactoferrin-related presentations are as follows:

The effect of talactoferrin on overall survival in prognostically important NSCLC subsets in a randomized, placebo-controlled phase II trial (abstract #7569)


• Saturday, June 4, 2:00 PM - 6:00 PM, Hall A

• General Poster Session. – Lung Cancer – Metastatic/Non-Small Cell

Mortality reduction by talactoferrin alfa (TLF) in severe sepsis with different types of infections (abstract #9024)

• J. Crawford, K. K. Guntupalli, N. C. Dean, P. E. Morris, R. K. Malik, J. P. Schaumberg

• Sunday, June 5, 8:00 AM - 12:00 PM, S102

• Poster Session – Patient and Survivor Care

• Sunday, June 5, 11:30 AM - 12:30 PM, S100bc

• Poster Discussion Session - Patient and Survivor Care

About talactoferrin

Talactoferrin is an oral biologic therapy with immunomodulatory and antibacterial properties, which is being studied for the treatment of cancer and severe sepsis. Talactoferrin has demonstrated promising activity in randomized, double-blind, placebo-controlled Phase II studies in NSCLC and in severe sepsis. Two Phase III trials with talactoferrin in NSCLC are ongoing, and one – the FORTIS-M trial – completed enrollment in March 2011. NSCLC is one of the most common types of cancer worldwide and the most frequent cause of cancer death. Agennix is also continuing the development of talactoferrin for the treatment of severe sepsis and plans to initiate a Phase II/III trial in that indication. Talactoferrin has been shown to be very well tolerated in these patient populations.

About Agennix

Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company’s most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer and in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix is also continuing the development of this program for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing, and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix’s registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.
This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. There can be no guarantee that the Company will move talactoferrin forward in development for severe sepsis in a timely manner, if at all. Even if the results from our later stage trials with talactoferrin, including the ongoing FORTIS-M trial in non-small cell lung cancer, are considered positive, they may not be sufficient to gain marketing approval in the United States or any other country, and the regulatory authorities may require additional information, data and/or further pre-clinical or clinical studies to support approval. In such event, there can be no guarantee that the Company will have or be able to obtain the financial resources to conduct any such additional studies or that such studies will yield results sufficient for approval. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Agennix™ is a trademark of the Agennix group.